NASDAQ:BCYC - Bicycle Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.00
  • Forecasted Upside: 7.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$42.99
▼ -0.51 (-1.17%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $46.00
▲ +7.00% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $46.00, with a high forecast of $58.00 and a low forecast of $36.00. The average price target represents a 7.00% upside from the last price of $42.99.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Bicycle Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2021JMP SecuritiesReiterated RatingBuy$53.00Medium
7/13/2021Piper SandlerBoost Price TargetOverweight$39.00 ➝ $46.00High
7/13/2021Canaccord GenuityBoost Price TargetBuy$30.00 ➝ $36.00High
5/11/2021OppenheimerBoost Price Target$38.00 ➝ $44.00Low
5/7/2021HC WainwrightBoost Price TargetBuy$31.00 ➝ $39.00Low
5/7/2021Piper SandlerBoost Price TargetOverweight$35.00 ➝ $39.00Low
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00Medium
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $58.00Medium
1/15/2021OppenheimerBoost Price TargetOutperform$27.00 ➝ $38.00High
1/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $31.00N/A
12/3/2020HC WainwrightReiterated RatingBuy$28.00High
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
9/22/2020OppenheimerReiterated RatingBuy$27.00High
9/10/2020Canaccord GenuityBoost Price TargetBuy$23.50 ➝ $25.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$25.00Low
7/21/2020OppenheimerReiterated RatingBuy$27.00High
6/24/2020OppenheimerReiterated RatingBuy$27.00Low
6/11/2020OppenheimerInitiated CoverageOutperform$27.00High
5/12/2020Canaccord GenuityReiterated RatingBuy$23.50Low
5/8/2020HC WainwrightReiterated RatingBuy$25.00High
4/17/2020HC WainwrightInitiated CoverageBuy$25.00Low
3/12/2020Canaccord GenuityInitiated CoverageBuy$23.50High
11/14/2019Roth CapitalInitiated CoverageBuy$17.00 ➝ $17.00High
9/30/2019Canaccord GenuitySet Price TargetBuy$22.00High
9/11/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$14.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
6/17/2019The Goldman Sachs GroupInitiated CoverageNeutralLow
6/17/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Low
6/17/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$22.00Medium
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Bicycle Therapeutics logo
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $42.99
Low: $42.02
High: $43.83

50 Day Range

MA: $35.18
Low: $27.95
High: $44.24

52 Week Range

Now: $42.99
Low: $17.68
High: $45.21

Volume

3,173 shs

Average Volume

150,236 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $46.00, suggesting a possible upside of 7.0%. Cantor Fitzgerald has the highest price target set, predicting BCYC will reach $58.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $36.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCYC will outperform the market and that investors should add to their positions of Bicycle Therapeutics.
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503. The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.